Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors

Abstract

The present invention is directed to novel heterocyclic benzo[c]chromene derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders mediated by one or more estrogen receptors. The compounds of the invention are useful in the treatment of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist.

1 . A compound of formula (I) 
       
         
           
           
               
               
           
         
         wherein 
           represents a single or double bond, 
         X is selected from the group consisting of O and S; 
       
       
         
           
           
               
               
           
         
          is pyrazine; 
         R 1  is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl and heteroaryl-alkyl; wherein the cycloalkyl, aryl, aralkyl, heteroaryl or heteroaryl-alkyl group is optionally substituted with one or more substituents independently selected from halogen, hydroxy, alkyl, alkoxy, —SH, —S(alkyl), SO 2 , NO 2 , CN, CO 2 H, R C , —OR C , —SO 2 —NR D R E , —NR D R E , NR D —SO 2 —R F , -(alkyl) 0-4 -C(O)NR D R E , (alkyl) 0-4 -NR D —C(O)—R F , -(alkyl) 0-4 -(Q) 0-1 -(alkyl) 0-4 -NR D R E , -(alkyl) 0-4 -(Q) 0-1 -(alkyl) 0-4 -C(O)—OR F , -(alkyl) 0-4 -(Q) 0-1 -(alkyl) 0-4 -C(O)—NR D R E  or -(alkyl) 0-4 -C(O)-(alkyl) 0-4 -C(O)—OR F ; 
         wherein R C  is selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl-alkyl, heterocycloalkyl and heterocycloalkyl-alkyl; 
         wherein the cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl-alkyl, heterocycloalkyl or heterocycloalkyl-alkyl group is optionally substituted with one or more substituents independently selected from halogen, hydroxy, alkyl, alkoxy, —SH, —S(alkyl), SO 2 , NO 2 , CN, CO 2 H, R C , —SO 2 —NR D R E , NR D R E , NR D —SO 2 —R F , -(alkyl) 0-4 -C(O)—NR D R E , -(alkyl) 0-4 -NR D —C(O)—R F , -(alkyl) 0-4 -(Q) 0-1 -(alkyl) 0-4 -NR D R E , -(alkyl) 0-4 -(Q) 0-1 -(alkyl) 0-4 -C(O)—OR F , -(alkyl) 0-4 -(Q) 0-1 -(alkyl) 0-4 -C(O)—NR D R E  or -(alkyl) 0-4 -C(O)-(alkyl) 0-4 -C(O)—OR F ; 
         wherein Q is selected from the group consisting of O, S, NH, N(alkyl) and —CH═CH—; 
         wherein R D  and R E  are each independently selected from the group consisting of hydrogen and alkyl; alternatively R D  and R E  are taken together with the nitrogen atom to which they are bound to form a 4 to 8 membered ring selected from the group consisting of heteroaryl or heterocycloalkyl; wherein the heteroaryl or heterocycloalkyl group is optionally substituted with one or more substituents independently selected from halogen, hydroxy, alkyl, alkoxy, carboxy, amino, alkylamino, dialkylamino, nitro or cyano; 
         wherein R F  is selected from the group consisting of hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, aryl, aralkyl, heteroaryl, heteroaryl-alkyl, heterocycloalkyl and heterocycloalkyl-alkyl; wherein the cycloalkyl, aryl, heteroaryl, heteroaryl-alkyl, heterocycloalkyl or heterocycloalkyl-alkyl group is optionally substituted with one or more substituents independently selected from halogen, hydroxy, alkyl, alkoxy, carboxy, amino, alkylamino, dialkylamino, nitro or cyano; 
         R 2  is selected from the group consisting of hydroxy, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl and heteroaryl-alkyl; wherein the cycloalkyl, aryl, aralkyl, heteroaryl or heteroaryl-alkyl group is optionally substituted with one or more substituents independently selected from halogen, hydroxy, alkyl, alkoxy, —SH, —S(alkyl), SO 2 , NO 2 , CN, CO 2 H, R C , —OR C , —SO 2 —NR D R E , —NR D R E , NR D —SO 2 —R F , -(alkyl) 0-4 -C(O)NR D R E , (alkyl) 0-4 -NR D —C(O)—R F , -(alkyl) 0-4 -(Q) 0-1 -(alkyl) 0-4 -NR D R E , -(alkyl) 0-4 -(Q) 0-1 -(alkyl) 0-4 -C(O)—OR F , -(alkyl) 0-4 -(Q) 0-1 -(alkyl) 0-4 -C(O)—NR D R E  or -(alkyl) 0-4 -C(O)-(alkyl) 0-4 -C(O)—OR F ; 
         alternatively, R 1  and R 2  are taken together with the carbon atom to which they are bound to form C(O); 
         n is an integer selected from 0 to 4; 
         each R 3  is independently selected from the group consisting of halogen, hydroxy, R C , amino, alkylamino, dialkylamino, nitro, cyano, SO 2 , —C(O)R G , —C(O)OR G , —OC(O)R G , —OC(O)OR G , —OC(O)N(R G ) 2 , —N(R G )C(O)R G , —OSi(R G ) 3 —OR G , —SO 2 N(R G ) 2 , —O-(alkyl) 1-4 -C(O)R G  and —O-(alkyl) 1-4 -C(O)OR G ; 
         wherein each R G  is independently selected from hydrogen, alkyl, aryl, aralkyl and 1,7,7-trimethyl-2-oxabicyclo[2.2.1]heptan-3-one; wherein the alkyl, aryl or aralkyl group is optionally substituted with one or more substituents independently selected from alkyl, halogenated alkyl, alkoxy, halogen, hydroxy, nitro, cyano, —OC(O)-alkyl or —C(O)O-alkyl; 
         alternatively two R G  groups are taken together with the nitrogen atom to which they are bound to form a heterocycloalkyl group; wherein the heterocycloalkyl group is optionally substituted with one or more substituents independently selected from halogen, hydroxy, alkyl, alkoxy, carboxy, amino, alkylamino, dialkylamino, nitro or cyano; 
         m is an integer selected from 0 to 4; 
         each R 4  is independently selected from the group consisting of halogen, hydroxy, R C , amino, alkylamino, dialkylamino, nitro, cyano, SO 2 , —C(O)R G , —C(O)OR G , —OC(O)R G , —OC(O)OR G , —OC(O)N(R G ) 2 , —N(R G )C(O)R G , —OSi(R G ) 3 —OR G , —SO 2 N(alkyl) 2 , —O-(alkyl) 1-4 -C(O)R G  and —O-(alkyl) 1-4 -C(O)OR G ; 
         R 5  is selected from the group consisting of hydrogen, alkyl, halogenated alkyl, aryl, aralkyl; 
         alternatively, R 3  and R 5  combined to form six membered ring; 
         provided that when   is a double bond, X is O, 
       
       
         
           
           
               
               
           
         
          is pyrazine, and R 1  and R 2  are taken together with the carbon atom to which they are bound to form C(O), then at least one of n or m is an integer selected from 1 to 4; 
         provided further that when   is a single bond, X is O, 
       
       
         
           
           
               
               
           
         
          is pyrazine, R 1  is hydrogen and R 2  is alkyl, then at least one of n or m is an integer selected from 1 to 4; 
         provided further that when   is a single bond, X is O, 
       
       
         
           
           
               
               
           
         
          is pyrazine, R 1  is hydrogen, R 2  is alkyl, n is 1 and m is 1, then R 3  and R 4  are other than methoxy or ethoxy; 
         provided further that when   is a double bond, X is O, 
       
       
         
           
           
               
               
           
         
          is pyrazine, R 1  and R 2  are taken together with the carbon atom to which they are bound to form C(O), n is 0 and m is 2, then each R 4  is not hydroxy or alkoxy. 
         provided further that when   is a double bond, X is O, 
       
       
         
           
           
               
               
           
         
          is pyrazine, R 1  and R 2  are taken together with the carbon atom to which they are bound to form C(O), R 3  and R 5  are combined into a six membered ring, then at least one of n or m is an integer selected from 1 to 4. 
       
       and pharmaceutically acceptable salts thereof. 
     
     
         2 . (canceled) 
     
     
         3 . The compound of  claim 1 , wherein R 1  is selected from the group consisting of hydrogen, lower alkyl, aryl or aralkyl; wherein the aryl or aralkyl group is optionally substituted with one to two substituents independently selected from halogen, hydroxy, lower alkyl, lower alkoxy, NO 2 , CN, and CO 2 H. 
     
     
         4 . The compound of  claim 1 , wherein R 2  is selected from the group consisting of hydroxy, lower alkyl, aryl or aralkyl; wherein the aryl or aralkyl is optionally substituted with one to two substituents independently selected from halogen, hydroxy, lower alkyl, lower alkoxy, NO 2 , CN, CO 2 H, R C , —OR C , —NR D R E , -(alkyl) 0-4 -C(O)NR D R E  and -(alkyl) 0-4 -(Q) 0-1 -(alkyl) 0-4 -NR D R E . 
     
     
         5 . The compound of  claim 1 , wherein R 1  and R 2  are taken together with the carbon atom to which they are bound to form C(O). 
     
     
         6 . The compound of  claim 1 , wherein R 3  is selected from the group consisting of halogen, hydroxy, R C , amino, (lower alkyl)-amino, di(lower alkyl)amino, nitro, cyano, —OC(O)R G , —OC(O)OR G , —OC(O)N(R G ) 2 , —OSi(R G ) 3 —OR G , —O-(alkyl) 1-4 -C(O)R G  and —O-(alkyl) 1-4 -C(O)OR G . 
     
     
         7 . The compound of  claim 1 , wherein R 4  is selected from the group consisting of halogen, hydroxy, R C , amino, (lower alkyl)-amino, di(lower alkyl)amino, nitro, cyano, —OC(O)R G , —OC(O)OR G , —OC(O)N(R G ) 2 , —OSi(R G ) 3 —OR G , —O-(alkyl) 1-4 -C(O)R G  and —O-(alkyl) 1-4 -C(O)OR G . 
     
     
         8 . The compound of  claim 1 , wherein R 5  is selected from the group consisting of hydrogen, lower alkyl, halogenated alkyl, aryl, aralky. 
     
     
         9 . (canceled) 
     
     
         10 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of  claim 1 . 
     
     
         11 - 15 . (canceled)